News Article

NEW DELHI – The Indian Patent Office has revoked a key patent for Novartis AG’s blockbuster heart failure drug, Vymada, in a decision that reverberates far beyond domestic intellectual property law, setting the stage for a potential multi-billion dollar clash at the crossroads of patent rights, public health, and international investment law.

The order, issued on September 12, 2025, by Deputy Controller of Patents and Designs D. Usha Rao, invalidated Patent No. 414518 covering the combination of sacubitril and valsartan. The decision not only opens the Indian market to generic competition, which could see prices plummet by over 70%, but also creates a critical test case for India’s regulatory sovereignty against the backdrop of international investor protections. While Novartis has yet to formally announce its next move, the prospect of an Investor-State Dispute Settlement (ISDS) claim under the India-Switzerland Bilateral Investment Treaty (BIT) looms large, transforming this patent dispute into a landmark legal battle.

A Decisive Application of India's Stringent Patent Law

The patent was struck down on grounds familiar to practitioners of Indian patent law: a lack of novelty and inventive step, coupled with insufficient disclosure under Section 25(2) of the Patent Act, 1970. However, the decision's most significant aspect is its robust application of Section 3(d), India’s controversial “anti-evergreening” provision.

Section 3(d) is designed to prevent pharmaceutical companies from extending patent monopolies through minor modifications to existing drugs unless the new form demonstrates "enhancement of the known efficacy." This clause was famously upheld by the Indian Supreme Court in its 2013 ruling in Novartis AG v. Union of India , a case involving the cancer drug Gleevec.

In the Vymada case, the Patent Office applied this stringent standard to Novartis's supramolecular complex. The Deputy Controller found that Novartis failed to provide the necessary evidence to clear this high bar, stating that "no experimental data, comparative studies or technical rationale have been provided to substantiate any enhanced efficacy." This finding reinforces the precedent set by the Supreme Court, requiring tangible proof of therapeutic superiority for new forms of known substances to be patentable. The successful post-grant opposition, notably led by the Indian Pharmaceutical Alliance, also signals the growing efficacy of collective industry action in challenging patents perceived as attempts to prolong market exclusivity without genuine innovation.

The International Investment Law Quagmire

What elevates this case from a standard patent revocation is the looming threat of an ISDS claim. Novartis, a Swiss multinational, has historically benefited from the protections afforded by the India-Switzerland BIT. However, the legal landscape was dramatically altered in 2017 when India unilaterally terminated 58 BITs, including its treaty with Switzerland, as part of a move to a new model BIT.

A "sunset clause" in the terminated treaty extends protection for 15 years—until 2032—but crucially, only for investments made before the 2017 termination. This creates the central jurisdictional puzzle: does the Vymada patent, granted in 2022, constitute a new investment falling outside the treaty's protection? Or can it be considered an integral part of Novartis's extensive pre-2017 investment portfolio in India, which includes manufacturing plants, R&D facilities, and a patent application for Vymada originally filed in 2007?

An arbitral tribunal would likely look to precedents like CSOB v. Slovakia to resolve this question. In that landmark case, the tribunal adopted a broad interpretation of "investment," holding that a specific transaction could fall under its jurisdiction if it forms "an integral part of an overall operation that qualifies as an investment."

A broad application of the CSOB principle could bring the Vymada patent under the BIT's umbrella, arguing that a patent is not a discrete, standalone asset but the culmination of a long-term R&D and commercial strategy established well before 2017. Conversely, a narrow interpretation would treat the 2022 patent grant as a distinct investment, placing it squarely outside the sunset clause's protection and summarily ending any potential ISDS claim.

Analyzing the Merits: Can India's Lawful Regulation Be a Treaty Breach?

Should Novartis overcome the jurisdictional hurdle, it would face the challenge of proving India breached its substantive obligations under the BIT, primarily the duty to provide Fair and Equitable Treatment (FET) and protection against indirect expropriation.

The FET claim would likely center on the argument that Novartis had a legitimate expectation that its duly granted patent would be protected. However, this argument appears weak. India's Patent Act, 1970, has explicitly included provisions for post-grant opposition since the TRIPS-compliant amendments of 2005. These procedures are a well-established and transparent part of India’s legal framework. An investor cannot reasonably claim a legitimate expectation that their patent would be immune from lawful, pre-existing domestic challenge mechanisms.

The ISDS tribunal's ruling in Eli Lilly v. Canada provides a powerful precedent in India's favor. In that case, the tribunal dismissed Eli Lilly's claim that the invalidation of its patents by Canadian courts violated NAFTA. The arbitrators emphasized that the "judicial applications of established domestic patent law can not constitute a breach of international investment obligations." The tribunal rejected the notion that a domestic court's application of its own patent laws, even if unfavorable to the investor, constituted arbitrary or discriminatory treatment. This reasoning would strongly support India’s position that the Patent Office was simply applying its own established laws, particularly the well-litigated Section 3(d).

Upholding Regulatory Sovereignty in Public Health

The Vymada revocation is a resounding assertion of India's regulatory sovereignty, particularly in the sensitive domain of public health and access to medicines. By consistently applying Section 3(d), India is executing a deliberate policy choice to balance IP protection with the need to prevent "evergreening" and promote affordable healthcare.

International arbitral jurisprudence has shown increasing deference to a state's right to regulate for public health. The Philip Morris v. Australia case, while decided on jurisdictional grounds, demonstrated the high bar for challenging legitimate public health measures, even those with significant impacts on IP rights. Although Australia incurred A$24 million in legal fees defending its tobacco plain-packaging laws, the case highlighted that non-discriminatory, public-interest regulations can withstand ISDS scrutiny.

The Eli Lilly precedent is even more pertinent, as it directly involved pharmaceutical patents. The tribunal's decisive rejection of the claims and its order for Eli Lilly to bear 75% of Canada's legal costs sent a clear message to investors: challenging legitimate, good-faith applications of domestic patent law through ISDS is a risky and potentially costly strategy.

Conclusion: A Legally Sound Defense Amid Lingering Risk

The revocation of the Vymada patent stands as a significant victory for India’s public health-oriented patent policy. By grounding its decision in established statutory provisions and judicial precedents, the Indian Patent Office has built a formidable defense against any potential ISDS challenge. The non-discriminatory application of its laws, particularly Section 3(d), positions the revocation as a predictable regulatory action rather than an arbitrary or unfair expropriation of rights.

While India's legal and procedural footing appears exceptionally strong, the mere threat of a costly and lengthy ISDS arbitration can have a chilling effect on state regulation. Should Novartis choose to initiate proceedings, the case will be a critical bellwether for the future of intellectual property, public health, and international investment law, testing the limits of corporate power and the resilience of national sovereignty.